Dithiocarbamates have emerged as potent carbonic anhydrase (CA) inhibitors in recent years. Given that CAs are important players in cellular metabolism, the objective of this work was to exploit the CA-inhibitory property of dithiocarbamates as a chemotherapeutic weapon against the Leishmania parasite. We report here strong antileishmanial activity of three hitherto unexplored metal dithiocarbamates, maneb, zineb, and propineb. They inhibited CA activity in Leishmania major promastigotes at submicromolar concentrations and resulted in a dose-dependent inhibition of parasite growth. Treatment with maneb, zineb, and propineb caused morphological deformities of the parasite and Leishmania cell death with 50% lethal dose (LD 50 ) values of 0.56 M, 0.61 M, and 0.27 M, respectively. These compounds were even more effective against parasites growing in acidic medium, in which their LD 50 values were severalfold lower. Intracellular acidosis leading to apoptotic and necrotic death of L. major promastigotes was found to be the basis of their leishmanicidal activity. Maneb, zineb, and propineb also efficiently reduced the intracellular parasite burden, suggesting that amastigote forms of the parasite are also susceptible to these metal dithiocarbamates. Interestingly, mammalian cells were unaffected by these compounds even at concentrations which are severalfold higher than their antileishmanial LD 50 s). Our data thus establish maneb, zineb, and propineb as a new class of antileishmanial compounds having broad therapeutic indices.
Leishmaniasis is a vector-borne disease caused by the protozoan parasite of the genus Leishmania. The disease is manifested in various clinical forms, ranging from self-healing skin ulcers to fatal infection of the visceral organs. With an estimated 1.3 million new cases and more than 20,000 deaths every year, leishmaniasis continues to be a threat to a huge population living in tropical and subtropical countries (1).To date, there is no antileishmanial vaccine for clinical use (2). Treatment options are also few. After several decades of successful use against visceral leishmaniasis, the pentavalent antimonials have become almost obsolete because of resistance developed against these drugs (3). This has led to the emergence of a second line of defense, including amphotericin B, paromomycin, and miltefosine (4). However, severe side effects, cases of disease relapse after an initial cure, and increasing signs of resistance have limited their efficacy (5-7). The liposomal formulation of amphotericin B (AmBisome) is by far the most effective treatment for leishmaniasis, having minimal side effects (8). Despite the effectiveness of AmBisome, its cost is a major point of concern, especially since this disease is prevalent in poorer sections of communities. Novel therapies against all forms of leishmaniasis are therefore urgently needed.Carbonic anhydrases (CAs) are a family of metalloenzymes that catalyze reversible hydration of CO 2 . By catalyzing this simple reaction, they play vital roles in a ...